531-09-9

Basic information

• Product Name: Bromopyramine
• Synonyms: Bromopyramine;(4-bromobenzyl)-(2-dimethylaminoethyl)-(2-pyridyl)amine;N-[(4-bromophenyl)methyl]-N',N'-dimethyl-N-pyridin-2-yl-ethane-1,2-diamine;N-[(4-bromophenyl)methyl]-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine
• CAS NO: 531-09-9
• Molecular Formula: C₁₆H₂₀BrN₃
• Molecular Weight: 334.25
• Mol File: 531-09-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 435°Cat760mmHg
• Flash Point: 216.9°C
• Appearance: /
• Density: 1.314g/cm³
• PKA: 9.00±0.28(Predicted)
• CAS DataBase Reference: Bromopyramine(CAS DataBase Reference)
• NIST Chemistry Reference: Bromopyramine(531-09-9)
• EPA Substance Registry System: Bromopyramine(531-09-9)

Safety Data

• Hazardous Substances Data: 531-09-9(Hazardous Substances Data)

Usage

General Description

Bromopyramine is a first-generation antihistamine that is used to relieve symptoms of allergies, such as sneezing, runny nose, and itchy/watery eyes. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms. Bromopyramine is available in oral and topical forms, and it is often used in combination with other medications to treat allergic rhinitis and other allergic conditions. While it is generally well-tolerated, common side effects of bromopyramine may include drowsiness, dizziness, dry mouth, and blurred vision. It is important to follow the dosing instructions provided by a healthcare professional and to avoid taking bromopyramine with alcohol or other medications that may cause drowsiness.

Upstream product

• 23826-72-4 N,N-dimethyl-N'-(pyridine-2-yl)ethane-1,2-diamine 
• 109-09-1 2-chloropyridine 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction

Focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3) are tyrosine kinases, which function as key modulators of survival and metastasis signals in cancer cells. Previously, we reported that small molecule chlorpyramine hydrochloride (C4) specifically targets the interaction between FAK and VEGFR3 and exhibits anti-tumor efficacy. In this study, we designed and synthesized a series of 1 (C4) analogs on the basis of structure activity relationship and molecular modeling. The resulting new compounds were evaluated for their binding to the FAT domain of FAK and anti-cancer activity. Amongst all tested analogs, compound 29 augmented anti-proliferative activity in multiple cancer cell lines with stronger binding to the FAT domain of FAK and disrupted the FAK-VEGFR3 interaction. In conclusion, we hope that this work will contribute to further studies of more potent and selective FAK-VEGFR3 protein-protein interaction inhibitors.